HER 2/neu expression and gene amplification in colon cancer

International Journal of Cancer

Volumn 105, Issue 6, 2003, Pages 796-802

  Nathanson, Daniel R ^a   Culliford IV, Alfred T ^a   Shia, Jinru ^a   Chen, Beiyun ^a   D'Alessio, Matthew ^a   Zeng, Zhao Shi ^a   Nash, Garrett M ^a   Gerald, William ^a   Barany, Francis ^b   Paty, Philip B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Gene quantification; LDR; PCR

Indexed keywords

LIGASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; AGED; COLONIC NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 0037495051     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11137     Document Type: Article

References (50)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 2001;344:783-92.
4. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
7. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
8. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
9. Caruso ML, Valentini AM. Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res 1996;16:3813-8.
10. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J. Sporadic amplification of the HER 2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988;48:1517-20.
11. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986;1:765-7.
12. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-55.
13. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele Jr G, Summerhayes IC. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989;4:1233-9.
14. Bruderlein S, van der Bosch K, Schlag P, Schwab M. Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosomes Cancer 1990;2:63-70.
15. Knyazev PG, Imyanitov EN, Chernitca OI, Nikiforova IF, Hanson KP. Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. Oncology 1992;49:162-5.
16. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y. Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 1989;44:802-5.
17. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.
18. Wang YP, Chen SQ, Xue KX. Amplification of C-erB-2 oncogene in colon carcinomas. Zhonghua Yi Xue Za Zhi 1994;74:536-8, 582.
19. Golijow C, Guerci A, Mouron S, Abba M, Dulout FN, Ottino A, Pianzola H. Activation of K-ras and c-erbB-2 protooncogenes in human colonic adenocarcinomas. Acta Gastroenterol Latinoam 2001; 31:71-6.
20. Barany F. The ligase chain reaction in a PCR world. PCR Methods Appl 1991;1:5-16.
21. Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci U S A 1991;88:189-93.
22. Barany F, Gelfand DH. Cloning, overexpression and nucleotide sequence of a thermostable DNA ligase-encoding gene. Gene 1991;109:1-11.
23. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J 1987;6:605-10.
24. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
25. Edorh A, Parache RM, Migeon C, N'Sossani B, Rihn B. Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies. Pathol Biol (Paris) 1995; 43:584-9.
26. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-15.
27. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-61.
28. Yang JL, Ow KT, Russell PJ, Ham JM, Crowe PJ. Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann Surg Oncol 1996;3:574-9.
29. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-13.
30. Sun XF, Carstensen JM, Stal O, Zhang H, Nordenskjold B. c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. Apmis 1995;103:309-15.
31. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
32. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88-92.
33. Shirai H, Ueno E, Osaki M, Tatebe S, Ito H, Kaibara N. Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. Anticancer Res 1995;15:2889-94.
34. Arnaout AH, Dawson PM, Soomro S, Taylor P, Theodorou NA, Feldmann M, Fendly BM, Shepard HM, Shousha S. HER 2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J Clin Pathol 1992; 45:726-7.
35. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER 2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61.
36. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 1995;10:661-8.
37. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S, Tahara E. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25:240-9.
38. Tannapfel A, Kuhn R, Kessler H, Wittekind C. Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. Anal Cell Pathol 1996;10:149-60.
39. Seidal T, Balaton AJ, Battifora H. Interpretation and quantificafion of immunostains. Am J Surg Pathol 2001;25:1204-7.
40. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER 2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
41. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994; 173:65-75.
42. Busmanis I, Feleppa F, Jones A, McGrath KM, Reed R, Collins J, Russell I, Begley CG. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 1994;26:261-7.
43. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-9.
44. Schnitt SJ, Jacobs TW. Current status of HER 2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001;116:806-10.
45. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
46. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 2001;33:278-82.
47. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-63.
48. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
49. Mass RKC. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. In: Proceedings of American Society of Clinical Oncology, New Orleans, LA, 2000. 19.
50. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974c-.